title: Beneficial effects of fluvastatin on progressive renal allograft dysfunction.
abstract: To assess the time-dependent changes in renal function in relation to antioxidant and lipid-lowering effects of fluvastatin in hyperlipidemic renal transplant recipients, 20 patients were treated with fluvastatin 40 mg/d for 12 months, after failure of a dietary program. Plasma malondialdehyde (MDA) levels and lipid profiles were evaluated in relation to serum creatinine and calculated creatinine clearances 18 months before and during the fluvastatin treatment. Mean baseline lipid values were: total cholesterol 318 mg/dL, triglycerides 212 mg/dL, LDL cholesterol 219 mg/dL, HDL cholesterol 58 mg/dL, apolipoprotein A 176 mg/dL, and apolipoprotein B 145 mg/dL. During 12 months of treatment, fluvastatin produced consistent and significant reductions in total and LDL cholesterol (-18.4% and -24.1%), triglycerides (-17.7%), and apolipoprotein B (-22.7%) as well as an increase in HDL cholesterol (12.3%) and apolipoprotein A (9.2%). Plasma MDA levels decreased by 41.8% (from 3.5 +/- 0.3 to 1.8 +/- 0.1 nmol/mL, P =.00002). Creatinine clearance, which had been declining at a rate of 0.32 mL/min/month during the previous 18 months before treatment, progressively improved during treatment, giving a positive slope of the creatinine clearance, which increased by 0.35 mL/min/month, (P =.016; 53.3 +/- 4.2 mL/min vs 49.8 +/- 4.1 mL/min pretreatment). Multiple linear regression analysis revealed that MDA was the parameter most closely associated with the variability in creatinine clearance. In conclusion, renal transplant patients with lipid abnormalities display renoprotective activity of fluvastatin, possibly due to its lipid-lowering and antioxidant effects.
authors.affiliation: Transplant Center, Laiko Hospital, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Konstadinidou
authors.forename: J N
authors.initials: JN
authors.lastname: Boletis
authors.forename: D
authors.initials: D
authors.lastname: Perrea
authors.forename: A
authors.initials: A
authors.lastname: Triantafyllou
authors.forename: V
authors.initials: V
authors.lastname: Filiopoulos
authors.forename: E
authors.initials: E
authors.lastname: Stamataki
authors.forename: A
authors.initials: A
authors.lastname: Kostakis
authors.forename: Ch P
authors.initials: ChP
authors.lastname: Stathakis
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003404:Creatinine / Q000097:blood / Q000652:urine; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000502:physiology*; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D012044:Regression Analysis
chemical_list: D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin; D008315:Malondialdehyde; D002784:Cholesterol; D003404:Creatinine